logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Cadent Therapeutics, Inc.


USPTO Granted Patents = 17



Forward Citations = 57

Loading Chart...
Loading Chart...

23 inventors (with patents filed for the assignee):

goldMedal David R Anderson (13 out of 46 patents)

silverMedal Robert A Volkmann (13 out of 74 patents)

bronzeMedal Frank S Menniti (10 out of 25 patents)

4.  Gregg F Keaney (7 out of 21 patents)

5.  Christopher Fanger (6 out of 29 patents)

6.  Janus Schreiber Larsen (4 out of 15 patents)

7.  Martin R Jefson (4 out of 19 patents)

8.  Thomas Amos Jacobsen (4 out of 4 patents)

9.  Steven C Leiser (3 out of 3 patents)

10.  Sam Malekiani (3 out of 3 patents)

11.  Timothy Piser (3 out of 7 patents)

12.  Dipak Vasantrao Amrutkar (3 out of 3 patents)

13.  Kelly Foster (3 out of 3 patents)

14.  Karin Sandager Nielsen (3 out of 10 patents)

15.  Yuelian Xu (1 out of 10 patents)


17 patents:

1. 11542264 - Heteroaromatic NMDA receptor modulators and uses thereof (2023-01-03),
2. 11541057 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2023-01-03),
3. 11274107 - NMDA receptor modulators and uses thereof (2022-03-15),
4. 11236104 - Heteroaromatic NMDA receptor modulators and uses thereof (2022-02-01),
5. 11116749 - Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B (2021-09-14),
6. 10973825 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2021-04-13),
7. 10781174 - N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B (2020-09-22),
8. 10774064 - Potassium channel modulators (2020-09-15),
9. 10752633 - Heteroaromatic NMDA receptor modulators and uses thereof (2020-08-25),
10. 10717728 - Potassium channel modulators (2020-07-21),
11. 10626122 - Heteroaromatic NMDA receptor modulators and uses thereof (2020-04-21),
12. 10584131 - Heteroaromatic NMDA receptor modulators and uses thereof (2020-03-10),
13. 10500205 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2019-12-10),
14. 10351553 - Potassium channel modulators (2019-07-16),
15. 10239835 - N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B (2019-03-26),
Company Overview
Cadent Therapeutics, Inc. is a biotechnology company based in Cambridge, MA, focused on developing innovative therapies for neurological and psychiatric disorders. The company specializes in the discovery and advancement of novel small molecules that target critical pathways in the brain, aiming to address unmet medical needs in conditions such as depression and anxiety. Cadent's research leverages cutting-edge science to create transformative treatments that enhance patient outcomes and improve quality of life.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

17 Patents

#158 in Cambridge, MA

#1,150 in Massachusetts

#18,894 in US

#35,918 in the World

Cambridge, MA (US)
Cambridge, MA, United States of America

Cadent Therapeutics, Inc.

Forward Citations = 57

23 inventors:

goldMedal David R Anderson (13 out of 46 patents)

silverMedal Robert A Volkmann (13 out of 74 patents)

bronzeMedal Frank S Menniti (10 out of 25 patents)

4.  Gregg F Keaney (7 out of 21 patents)

5.  Christopher Fanger (6 out of 29 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cadent Therapeutics, Inc.. Retrieved from https://idiyas.com/company/cadent-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…